Isolation and characterization of Mesenchymal Stem Cells from pituitary tumours by Orciani, Monia et al.
IJAE 
Vo l .  118 ,  n .  2  (Supp lem ent) :  149,  2013
© 2013 Firenze University Press 
ht tp://www.fupress .com/ijae
ITALIAN JOURNAL OF ANATOMY AND EMBRYOLOGY
Isolation and characterization of Mesenchymal Stem 
Cells from pituitary tumours
Monia Orciani1, Raffaella Lazzarini1, Danila Cianciosi1, Giorgio Arnaldi2 and Roberto Di Primio1
1 Dept. of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy
2 Clinic of Endocrinolgy, Università Politecnica delle Marche, Ancona, Italy
In the past few years the introduction of the cancer stem cells (CSCs) notion 
opened new perspectives for the diagnosis and cure of solid tumors. According to 
this theory, CSCs originate from mutated stem cells, maintaining the self-renewal and 
differentiative abilities. Therefore, the development of specific therapies targeted at 
CSCs holds hope for improvement of survival and quality of life of cancer patients. 
Actually, no informations are available about stem cells and cancer stem cells on pitu-
itary tumours.
This work depicts some essential features of stem cells isolated from pituitary ade-
nomas. Six tumour biopsies (3: GH-secreting; 3: non secreting) were collected and cul-
tured with a specific culture medium. Cell growth and morphology were monitored 
and cells were subjected to analyses for stemness determination (immunophenotype, 
gene expression and differentiative potential) [1, 2] and GH secretion. Cells showed a 
stem-like immunophenotype, the expression of Oct-4, Sox-2, Nanog and Klf-4 and the 
ability to differentiate towards osteogenic, chondrogenic and adipogenic lineages. The 
hormone secretion ended after two weeks culturing. Even if further studies are needed 
for the fully comprehension of the specific nature of these cells and on their role on 
tumour onset and maintenance, this study opens to the possibility of isolation of stem 
cells from pituitary tumour, allowing a molecular targeting of it.
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